CHRFAM7A and COVID-19: In contrast, 21 (57%) COVID-19 patients and 10 (71%) healthy controls expressed the human dominant negative duplicate CHRFAM7A. COVID-19 patients tended to have a decreased expression of CHRFAM7A compared to healthy controls (1.35 ± 2.5 versus 3.45 ± 4.2, p = 0.06) (Fig. 1A).